Abstract
Long-term safety of apremilast treatment in psoriasis and psoriatic arthritis patients: pooled analysis for 156 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-3 phase 3 trials
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
